What Has Been the Growth of the Artificial Pancreas Device System Market So Far?
The artificial pancreas device system market has seen considerable growth due to a variety of factors.
• The artificial pancreas device system market has experienced strong growth in recent years. It is expected to rise from $1.81 billion in 2024 to $2.07 billion in 2025, with a compound annual growth rate (CAGR) of 14.1%.
Contributing factors include rising investment inflows, growing government initiatives in clinical research, higher demand for automated glycemic control systems, intensive R&D by industry players, and an expanding elderly population.
What Are the Future Growth Projections for the Artificial Pancreas Device System Market?
The artificial pancreas device system market is expected to maintain its strong growth trajectory in upcoming years.
• The artificial pancreas device system market is anticipated to grow rapidly, reaching $3.48 billion by 2029, at a CAGR of 13.9%.
Factors contributing to this growth include the rising incidence of diabetes and pancreatic cancer, the increased demand for minimally invasive drug delivery systems, and ongoing innovations in diabetes management technology. Trends include technological breakthroughs, growing research efforts, increased product approvals, and the rise in teleconsultancy for follow-up care.
What Are The Core Factors Supporting Growth In The Artificial Pancreas Device System Market?
The artificial pancreas device system market is expected to grow due to the increasing prevalence of pancreatic cancer. Pancreatic cancer, influenced by lifestyle, genetic, and environmental factors, is becoming more common. Artificial pancreas systems help diabetes patients manage blood sugar levels by automatically monitoring glucose and delivering insulin. Cancer Australia reported an increase in pancreatic cancer cases in 2023, with 4,506 new diagnoses, up from 3,751 over the previous five years. This rise in cases will further propel the demand for artificial pancreas systems.
What Are The Major Segments Within The Global Artificial Pancreas Device System Market?
The artificial pancreas device system market covered in this report is segmented –
1) By Device Type: Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems
2) By Treatment Type: Bi-Hormonal, Insulin Only, Hybrid
3) By End-User: Hospitals, Medical Centers, Other End-Users
Subsegments:
1) By Threshold Suspend Device Systems: Insulin Pump with Threshold Suspend, Continuous Glucose Monitoring (CGM) Integrated Systems
2) By Control-To-Range Systems: Hybrid Closed-Loop Systems, Insulin Delivery Systems with Range Control, Real-Time Glucose Adjustment Systems
3) By Control-To-Target Systems: Fully Closed-Loop Artificial Pancreas Systems, Insulin Pumps with Targeted Glucose Control, Automated Glucose Regulation Systems
Pre-Book The Artificial Pancreas Device System Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Artificial Pancreas Device System Market?
In the artificial pancreas device system market, companies are developing automated insulin delivery systems to improve diabetes management by continuously monitoring blood glucose levels and automatically administering insulin. These systems aim to reduce the burden of manual blood sugar monitoring and insulin injection. For example, in May 2023, Beta Bionics, a US-based medical device company, received FDA 510(k) clearance for its iLet Insulin-Only Bionic Pancreas System. This device autonomously adjusts insulin doses based on glucose levels, providing more precise and convenient diabetes management for users.
Who Are the Key Players In The Artificial Pancreas Device System Market?
Major companies operating in the artificial pancreas device system market are:
• Johnson & Johnson
• Abbott Laboratories
• Medtronic plc
• DexCom Inc.
• Insulet Corporation
• Tandem Diabetes Care Inc.
• Juvenile Diabetes Research Foundation (JDRF)
• Beta Bionics Inc.
• Glooko Inc.
• Bigfoot Biomedical Inc.
• CeQur SA
• Medtrum Technologies Inc.
• Diabeloop SA
• Beta-O2 Technologies Ltd
• Pancreum Inc.
• TypeZero Technologies LLC
• Inreda Diabetic B.V.
• Defymed SAS
• Admetsys Corporation
• DreaMed Diabetes Ltd
What Is The Most Dominant Region In The Artificial Pancreas Device System Market?
North America was the largest region in the artificial pancreas device system market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial pancreas device system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
